NCT04047303 is a Phase 1 clinical trial of CC-90010 in Astrocytoma, sponsored by Celgene.

Who is sponsoring NCT04047303?

NCT04047303 is sponsored by Celgene.

What drugs are being tested in NCT04047303?

Interventions in NCT04047303: CC-90010.

What condition does NCT04047303 study?

NCT04047303 studies Astrocytoma, Glioblastoma.

Is NCT04047303 still recruiting?

NCT04047303 is currently terminated. Last updated 5 July 2024.

Last reviewed 2024-07-05 · How we verify

NCT04047303

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

Terminated Phase 1 Last updated 5 July 2024

What this trial tests

Phase 1 trial testing CC-90010 in Astrocytoma in 20 participants. Terminated before completion.

Timeline

2 January 2020

Primary endpoint
3 June 2024

3 June 2024

Quick facts

Lead sponsor	Celgene
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	2 January 2020
Primary completion	3 June 2024
Estimated completion	3 June 2024
Sites	4 locations across United States, Spain

Drugs / interventions tested

CC-90010 — full drug profile →

Conditions studied

Astrocytoma — all drugs for Astrocytoma →
Glioblastoma — all drugs for Glioblastoma →

Sponsor

Celgene — full company profile →

Who can join

18 and older, any sex, with Astrocytoma or Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects with progressive or recurrent WHO Grade II Diffuse Astrocytoma, Grade III Anaplastic Astrocytoma and recurrent Glioblastoma who have failed radiation and chemotherapy, and who are candidates for surgical tumor resection as part of their salvage regimen (planned salvage resection).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Epigenetics-targeted drugs: current paradigms and future challenges.
Dai W, Qiao X, Fang Y, Guo R, et al · · 2024 · cited 131× · PMID 39592582 · DOI 10.1038/s41392-024-02039-0
Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy.
Wang ZQ, Zhang ZC, Wu YY, Pi YN, et al · · 2023 · cited 128× · PMID 37926722 · DOI 10.1038/s41392-023-01647-6
Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends.
Nepali K, Liou JP. · · 2021 · cited 122× · PMID 33840388 · DOI 10.1186/s12929-021-00721-x
Pharmacological targeting of the cancer epigenome.
Mabe NW, Perry JA, Malone CF, Stegmaier K. · · 2024 · cited 36× · PMID 38937652 · DOI 10.1038/s43018-024-00777-2
Super-enhancers complexes zoom in transcription in cancer.
Wang M, Chen Q, Wang S, Xie H, et al · · 2023 · cited 32× · PMID 37501079 · DOI 10.1186/s13046-023-02763-5
Targeting lysine acetylation readers and writers.
Zhou MM, Cole PA. · · 2025 · cited 28× · PMID 39572658 · DOI 10.1038/s41573-024-01080-6
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Moreno V, Manuel Sepúlveda J, Reardon DA, Pérez-Núñez Á, et al · · 2023 · cited 27× · PMID 36455228 · DOI 10.1093/neuonc/noac263
Early Therapeutic Interventions for Newly Diagnosed Glioblastoma: Rationale and Review of the Literature.
Waqar M, Trifiletti DM, McBain C, O'Connor J, et al · · 2022 · cited 27× · PMID 35119629 · DOI 10.1007/s11912-021-01157-0

Verify or expand the search:

Other trials of CC-90010

Trials testing the same drug.

NCT05678283 — A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors · Phase 1 · withdrawn
NCT04324840 — A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagno · Phase 1 · terminated
NCT03220347 — A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advan · Phase 1 · terminated

Other recruiting trials for Astrocytoma

Currently open trials in the same condition.

NCT06989086 — FearLess in NeuroOncology · NA · recruiting
NCT06614855 — A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant G · Phase 1 · active not recruiting
NCT06797661 — Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients with Brain Lesions. · NA · recruiting
NCT06344130 — Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma · Phase 1 · recruiting
NCT05879367 — Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma · Phase 1 · recruiting

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04047303 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 5 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04047303.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing